Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA

Détails

Ressource 1Télécharger: 9079.1-20150302103854-covered-e0fd13ba177f913fd3156f593ead4cfd.pdf (848.57 [Ko])
Etat: Public
Version: Final published version
Licence: Non spécifiée
ID Serval
serval:BIB_D4C4AC55EE07
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA
Périodique
Journal of Clinical Investigation
Auteur⸱e⸱s
Rizzardi G. P., De Boer R. J., Hoover S., Tambussi G., Chapuis A., Halkic N., Bart P. A., Miller V., Staszewski S., Notermans D. W., Perrin L., Fox C. H., Lange J. M., Lazzarin A., Pantaleo G.
ISSN
0021-9738 (Print)
Statut éditorial
Publié
Date de publication
03/2000
Peer-reviewed
Oui
Volume
105
Numéro
6
Pages
777-82
Langue
anglais
Notes
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't --- Old month value: Mar
Résumé
Effective therapeutic interventions and clinical care of adults infected with HIV-1 require an understanding of factors that influence time of response to antiretroviral therapy. We have studied a cohort of 118 HIV-1-infected subjects naive to antiretroviral therapy and have correlated the time of response to treatment with a series of virological and immunological measures, including levels of viral load in blood and lymph node, percent of CD4 T cells in lymph nodes, and CD4 T-cell count in blood at study entry. Suppression of viremia below the limit of detection, 50 HIV-1 RNA copies/mL of plasma, served as a benchmark for a successful virological response. We employed these correlations to predict the length of treatment required to attain a virological response in each patient. Baseline plasma viremia emerged as the factor most tightly correlated with the duration of treatment required, allowing us to estimate the required time as a function of this one measure.
Mots-clé
Adult Anti-HIV Agents/*administration & dosage/pharmacology/therapeutic use CD4 Lymphocyte Count/drug effects CD4-Positive T-Lymphocytes/pathology Carbamates Cohort Studies Dideoxynucleosides/administration & dosage/pharmacology/therapeutic use HIV Infections/*drug therapy/immunology/virology HIV Protease Inhibitors/administration & dosage/pharmacology/therapeutic use HIV-1/*isolation & purification HIV-1 Reverse Transcriptase/antagonists & inhibitors Humans Lamivudine/administration & dosage/pharmacology/therapeutic use Lymph Nodes/virology Nelfinavir/administration & dosage/pharmacology/therapeutic use RNA, Viral/*blood Reverse Transcriptase Inhibitors/administration & dosage/pharmacology/therapeutic use Saquinavir/administration & dosage/pharmacology/therapeutic use Stavudine/administration & dosage/pharmacology/therapeutic use Sulfonamides/administration & dosage/pharmacology/therapeutic use Time Factors *Viral Load Viremia/*drug therapy Zidovudine/administration & dosage/pharmacology/therapeutic use
Pubmed
Web of science
Open Access
Oui
Création de la notice
25/01/2008 16:13
Dernière modification de la notice
29/03/2023 7:16
Données d'usage